

FOR IMMEDIATE RELEASE

QT Vascular seeks CE Mark approval for Drug-Coated Version of Chocolate[®] Balloon Catheter

- One of the key milestones as outlined in IPO prospectus
- Drug-Coated Chocolate (Chocolate Touch[™]) combines the long term benefits of drug coating with the Chocolate's mechanical advantages of minimizing dissections and bail out stenting as demonstrated in a recent clinical study¹.
- CE Mark approval is not expected this year. Typical review time for this class of products is at least 12-18 months.

Singapore, 24 July 2014 – Catalyst-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, has applied for CE marking approval ("CE Mark") with respect to the Paclitaxel-Coated Chocolate[®] Balloon Catheter (Chocolate Touch[™]). Chocolate Touch[™] is a second generation drug coated balloon which carries a proprietary drug coating process. The CE Mark approval, which is not expected this year, will allow for marketing of the product in the European Union.

New balloon catheters recently introduced to the market are coated with drugs, which helps to inhibit arterial cell wall growth and prevent recurrent blockages. These medical devices are known as drug-coated balloons ("DCB"). However, the current generation of DCBs may have significant limitations. A recent study² showed that the use of conventional DCBs can result in a high rate of dissections and bail-out stenting. Severe dissections often require additional treatment such as bail-out stenting.

Chocolate[®] was designed to minimize trauma to blood vessels. In contrast, first-generation DCBs use conventional balloons which are known to cause acute trauma to vessel walls evident in recoil and dissections. In addition, the use of Paclitaxel in DCBs was shown to increase the effectiveness of preventing blockages from recurring. Chocolate Touch[™], the second generation drug coated balloon from QT Vascular, builds on the success of the Chocolate[®] platform and delivers a safe and proven drug Paclitaxel. In the Group's pre-clinical studies, addition of drug coating to the balloon resulted in ten-fold reduction in vessel re-narrowing compared to conventional balloons.

Chocolate Touch[™] represents the latest addition to the Group's product pipeline. The Group has previously announced on 5 June 2014 that its wholly owned US subsidiary, TriReme Medical LLC, received notification from the United States Food and Drug Administration (FDA) of 510(K) clearance to market the Chocolate[®] Percutaneous Transluminal Coronary Angioplasty Balloon Catheter ("Chocolate PTCA") in the United States, for the treatment of blocked arteries for coronary vascular diseases. Other products in the pipeline include the Silk PTA balloon catheter ("Silk PTA"), a version of Chocolate[®] PTA that is made for intervention in longer lesions. The Silk PTA is currently at the design feasibility stage, with CE Mark submission targeted for the first quarter of 2015.

Dr. Eitan Konstantino, the Group's Chief Executive Officer, commented, *“The submission of the CE Mark application for Chocolate Touch™ represents a key milestone towards the commercialization of our second generation drug-coated balloons. The combination of our low rate of dissections and bail out stenting with the long term effect of the drug is powerful. Looking ahead, Chocolate Touch™ will enable us to remain competitive in the medical device market for peripheral artery diseases.”*

1. Das T for Mustapha J. Chocolate® Bar, Leipzig Interventional Course, 28-31 January, 2014
2. Werk M et al. PACIFIER Trial, Circ Cardiovasc Interv. 2012;5:831-840

- End -

About Peripheral Artery Disease

Peripheral artery disease is an obstruction of the blood flow in the peripheral arteries. It occurs commonly in the arteries of the pelvis and legs. It can result from the slow accumulation of plaque over time or the sudden formation of a blood clot which leads to arterial narrowing or blockage of a vessel.

About Coronary Artery Disease

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.

About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

For more information, please refer to: <http://www.qtvascular.com/>

**Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd**

Kamal SAMUEL, kamal@financialpr.com.sg

Mark LIN, marklin@financialpr.com.sg

Tel: (65) 6438 2990 Fax: (65) 6438 0064

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.